Impact News +++ Milliarden-Deal: Accenture übernimmt Netzwerkanalyse-Spezialisten Ookla (Heise) +++ ZIFF DAVIS Aktie -10,50%

MODERNA Aktie

>MODERNA Aktienkurs

42.915 EUR -5.1% (TradegateBSX)

Ask: 42.94 EUR / 70 Stück

Bid: 42.85 EUR / 80 Stück

Tagesumsatz: 49934 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

MODERNA Aktie über LYNX handeln

Intraday

1 Jahr

>MODERNA Performance

1 Woche: 0%

1 Monat: +20,2%

3 Monate: +99,3%

6 Monate: +109,4%

1 Jahr: +48,3%

laufendes Jahr: +61,6%

>MODERNA Aktie

Name:

MODERNA INC. DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US60770K1079 / A2N9D9

Symbol/ Ticker:

0QF (Frankfurt) / MRNA (NASDAQ)

Kürzel:

FRA:0QF, ETR:0QF, 0QF:GR, NASDAQ:MRNA

Index:

S&P500

Webseite:

https://www.modernatx.com..

Profil:

Moderna, Inc. is a biotechnology company specializing in the research, development, and provision of messenger RNA (mRNA) medicines in the United States, Europe, and internationally. Its primary funct..
>Volltext..

Marktkapitalisierung:

18000.33 Mio. EUR

Unternehmenswert:

14142.56 Mio. EUR

Umsatz:

1676.65 Mio. EUR

EBITDA:

-2465.81 Mio. EUR

Nettogewinn:

-2433.9 Mio. EUR

Gewinn je Aktie:

-6.26 EUR

Schulden:

1125.53 Mio. EUR

Liquide Mittel:

2238.98 Mio. EUR

Operativer Cashflow:

-1615.41 Mio. EUR

Bargeldquote:

2.92

Umsatzwachstum:

-47.05%

Gewinnwachstum:

30.15%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 8.540.887 USD.

Suchwörter:

MODERNA

Letzte Datenerhebung:

04.03.26

>MODERNA Kennzahlen

Aktien/ Unternehmen:

Aktien: 394.94 Mio. St.

Frei handelbar: 91.46%

Leerverk. Aktien: 18.26%

Rückkaufquote: -0.17%

Mitarbeiter: 4700

Umsatz/Mitarb.: 0.36 Mio. EUR

Analysten:

Analystenrating: Neutral

Kursziel: -19.66%

Bewertung:

KGV: -

KGV lG: -

KUV: 10.63

KBV: 2.32

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 44.29%

Gewinnmarge: -145.16%

Operative Marge: -158.13%

Managementeffizenz:

Gesamtkaprendite: -21.31%

Eigenkaprendite: -28.87%

>MODERNA Peer Group

Gesundheit, Medizin für Bakterielle- & Pilzinfektionen/ Antibiotika, mRNA- Forschung/ Impfstoffe, Onkologie/ Krebs- Behandlung, Impfstoffentwicklung/ Impfstoffhersteller, Covid 19- Behandlung

>MODERNA Chart & Kurs - NASDAQ

>MODERNA News

04.03.26 - 05:02	Insiderhandel: Chief Legal Officer verkauft Aktien von Moderna im Wert von 726047 USD (Insiderkauf)
	Klinger, Shannon Thyme - Vorstand - Tag der Transaktion: 2026-03-02...

04.03.26 - 03:06	CrowdStrike, Mobix Labs, Micron Technology, Target And Moderna: Why These 5 Stocks Are On Investors′ Radars Today (Benzinga)
	U.S. stocks finished Tuesday lower as mounting tensions in the conflict with Iran weighed on sentiment. The Dow Jones Industrial Average slid 0.8% to 48,501.27. Importance Rank: 1 read more...

04.03.26 - 00:36	Moderna Stock Jumps 10% After Hours: Here′s Why (Benzinga)
	Moderna shares are rising in Tuesday's after-hours session after the company announced it reached a settlement agreement. Importance Rank: 1 read more...

03.03.26 - 23:36	Moderna’s stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline (MarketWatch)
	The deal would provide 'certainty' for Moderna's vaccine portfolio....

03.03.26 - 23:21	Moderna surges after hours on patent settlement with Arbutus and Genevant (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.03.26 - 23:18	Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus (AFX)
	WASHINGTON (dpa-AFX) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary......

03.03.26 - 22:54	Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant (WSJ EN)
	The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor....

03.03.26 - 22:48	Moderna to Pay Almost $1 Billion to Settle Arbutus Litigation (Bloomberg)
	Moderna Inc. agreed to pay $950 million to settle all litigation worldwide with Arbutus Biopharma Corp. and Genevant Sciences GmbH over the company's existing and future vaccines, with no future royalties owed....

03.03.26 - 22:42	Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute (Reuters EN)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.03.26 - 22:31	Moderna, Inc.: Moderna Resolves Global Patent Litigation with Arbutus/Genevant (Accesswire)
	Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026District Court's Section 1498 decision to be appealed to the Federal C......

03.03.26 - 22:17

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna (GlobeNewswire EN)

BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that they have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna's unauthorized use of Genevant's and Arbutus' LNP delivery technology in its COVID-19 vaccines, including Spikevax®....

03.03.26 - 22:17

Roivant Announces Genevant Sciences′ and Arbutus Biopharma′s $2.25 Billion Global Settlement With Moderna (GlobeNewswire EN)

BASEL, Switzerland and LONDON and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant, and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna's unauthorized use of Genevant's and Arbutus' LNP delivery technology in its COVID-19 vaccines, including Spikevax®....

02.03.26 - 15:01	MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot (Zacks)
	Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone vaccines....

27.02.26 - 21:45	European health agency recommends approving Moderna′s combined flu, COVID vaccine (The Hill)
	The European Medicines Agency (EMA) announced Friday it has recommended Moderna's combined mRNA COVID-19 and flu vaccine be granted market authorization in the European Union, marking the first time the combined respiratory viral vaccine will be approved. "EMA has recommended granting a marketing authorisation in the European Union (EU) for mCombriax, a messenger RNA vaccine......

27.02.26 - 18:12	Moderna: Kombi-Impfung für Grippe und Covid erhält Zulassung (Der Aktionaer)
	Gute Nachrichten für Moderna: Die EU-Arzneimittelbehörde EMA hat grünes Licht gegeben für den ersten Kombi-Impfstoff gegen Corona und Grippe. Der Wirkstoff solle für Menschen ab 50 Jahren zugelassen werden, teilte die Behörde in Amsterdam mit....

27.02.26 - 15:33	EMA recommends authorization of Moderna combination COVID/flu vaccine (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.02.26 - 15:15	Impfstoff: Moderna erhält EU–Zulassung für Impfstoff gegen Covid und Grippe (Handelsblatt)
	Die Europäische Arzneimittelagentur empfiehlt den ersten Kombinationsimpfstoff gegen Grippe und Covid von Moderna – ein wichtiger Erfolg für den Konzern....

27.02.26 - 13:06	Moderna, Inc.: European Medicines Agency′s Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna′s mRNA Combination Vaccine Against Influenza and COVID-19 (Accesswire)
	mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positi......

27.02.26 - 12:12	Moderna Gets EU Approval for mRNA Combination Covid-Flu Shot (Bloomberg)
	European regulators have approved Moderna Inc.'s novel combination flu and Covid shot, handing a victory to the embattled vaccine maker that's faced heavy resistance to its new immunizations in the US....

26.02.26 - 02:01	Insiderhandel: President verkauft Aktien von Moderna im Wert von 7814840 USD (Insiderkauf)
	Hoge, Stephen - Vorstand - Tag der Transaktion: 2026-02-23...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer ein blindes Pferd verkaufen will, lobt die Füße. - Bauernregel - Bauernweisheit

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram